Nature Biotechnology's academic spinouts 2023

News Feature

• 

  Congruence Therapeutics: finding a fix for misfolded proteins

  Stabilizing the unstable may be the road to therapeutics for unmet needs.

  • Michael Eisenstein

  News Feature7 Sep 2023 Nature Biotechnology
• 

  Septerna: making another run on GPCRs

  Some 700 approved therapies in the United States — roughly a third of all drugs on the market — target G-protein-coupled receptors (GPCRs). Now advances in high-throughput and structure-based screening are sparking a second golden age of GPCR-based drug discovery.

  • Charles Schmidt

  News Feature14 Sep 2023 Nature Biotechnology
• 

  Peptone: finding opportunity in disorder

  Combining experimental and computational tools, this company is targeting disordered regions of proteins previously thought to be undruggable.

  • Michael Eisenstein

  News Feature19 Sep 2023 Nature Biotechnology
• 

  Vector BioPharma: resurrecting adenoviral gene delivery

  Two veteran protein engineers team up to create a new gene-delivery vehicle.

  • Laura DeFrancesco

  News Feature26 Sep 2023 Nature Biotechnology
• 

  Cartography Biosciences and Nested Therapeutics: Diamonds in the rough

  Two start-ups are taking a deep dive into cancer genomes to unearth new therapeutic targets.

  • Laura DeFrancesco

  News Feature2 Oct 2023 Nature Biotechnology
• 

  Photys Therapeutics: customizing phosphorylation via molecular matchmaking

  Bifunctional molecules that link kinase enzymes with new targets could rewire disease-related cellular processes

  • Michael Eisenstein

  News Feature4 Oct 2023 Nature Biotechnology
• 

  Pheast Therapeutics: Another bite at the apple

  The Weissman lab is taking another swing at ‘don’t eat me’ signaling. They think they have a new and better target.

  • Laura DeFrancesco

  News Feature5 Oct 2023 Nature Biotechnology